Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria.
Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria.
复制标题
DOI：
10.1371/journal.pone.0276639
复制
发表时间：
2022
期刊：
影响因子：
3.7
通讯作者：
中科院分区：
文献类型：
--
作者：
羟基脲（HU）是一种循证疗法，是目前治疗镰状细胞病（SCD）最有效的药物。HU在高收入国家广泛使用，从而降低了发病率和死亡率。在尼日利亚，HU由医生开处方，而护士主要参与咨询患者以确保依从性。在尼日利亚，尚未充分评价利用的程度和决定因素。评估HU的使用频率以及影响SCD的医疗保健提供者、患者和护理人员利用率的因素。在线和面对面进行问卷调查，以评估HU使用频率以及促进和限制其使用的因素。使用IBM SPSS软件23版对数据进行描述性统计分析，结果以频率表和百分比表示。共有137名医生，137名护士和237名患者/护理人员回答了调查。过去6个月内医生开出HU的比例为64（46.7%），43（31.4%）名护士提供咨询，36（15.6%）名患者服用HU。在医生中，足够的知识（91.3%），临床效益和安全性（94.8%），并在管理指南中包含HU（86.9%）是处方的动机，而知识不足（60.9%）和不了解治疗指南（68.6%）构成了障碍。护理人员中，减少危机（91.6%）和安全（64.8%）是主要的动机，而障碍是高成本（79.1%）和加强监护（63.1%）的HU治疗。在患者中，主要的动机是减少危机（80.3%），而知识不足（93.2%），药物价格高（92.2%），而监测（91.2%），不可用（87.7%）和副作用（83.9%）是使用HU的主要障碍。HU处方和利用率在医疗保健提供者和患者中仍然很差。不充分的知识，不提供和高成本的HU以及不了解治疗指南构成处方和利用的主要障碍。
Hydroxyurea (HU) is an evidence-based therapy that is currently the most effective drug for sickle cell disease (SCD). HU is widely used in high-income countries with consequent reduction of morbidity and mortality. In Nigeria, HU is prescribed by physicians while nurses are mainly involved in counseling the patients to ensure adherence. The extent of utilization and the determinant factors have not been sufficiently evaluated in Nigeria. To assess the frequency of use of HU and factors affecting utilization among healthcare providers, patients, and caregivers for SCD. A questionnaire was administered online and in- person to assess the frequency of HU use and the factors that promote and limit its use. The data were analyzed by descriptive statistics using IBM SPSS software version 23 and the result was presented in frequency tables and percentages. A total of 137 physicians, 137 nurses, and 237 patients/caregivers responded to the survey. The rate of prescription of HU by doctors in the past 6 months was 64 (46.7%), 43 (31.4%) nurses provided counseling and 36 (15.6%) patients were on HU. Among doctors, adequate knowledge (91.3%), clinical benefits and safety (94.8%), and inclusion of HU in management guidelines (86.9%) were motivators for prescribing it while inadequate knowledge (60.9%) and unawareness of treatment guidelines (68.6%) constituted barriers. Among nurses, reduction of crisis (91.6%) and safety (64.8%) were the major motivators while barriers were high cost (79.1%) and intensive monitoring (63.1%) of HU treatment. Among the patients, the major motivator was the reduction of crises (80.3%) while poor knowledge (93.2%), high cost of the drug (92.2%) while monitoring (91.2%), non-availability (87.7%) and side effects (83.9%) were the major barriers for the utilization of HU. HU prescription and utilization are still poor among healthcare providers and patients. Inadequate knowledge, non-availability and high cost of HU as well as unawareness of treatment guidelines constitute major barriers to prescription and utilization.
登录
查看更多内容
影响因子：
3.7
作者：
Chianumba RI;Ofakunrin AOD;Morrice J;Olanrewaju O;Oniyangi O;Kuliya-Gwarzo A;Nnebe-Agumadu U;Isa HA;Nnodu OE
通讯作者：
Nnodu OE
影响因子：
24.7
作者：
Nnodu, Obiageli E.;Sopekan, Alayo;Piel, Frederic B.
通讯作者：
Piel, Frederic B.
影响因子：
3.7
作者：
Okocha EC;Gyamfi J;Ryan N;Babalola O;Etuk EA;Chianumba R;Nwegbu M;Isa H;Madu AJ;Adegoke S;Nnebe-Agumandu U;Brown B;Peprah E;Nnodu OE
通讯作者：
Nnodu OE
影响因子：
2
作者：
Ofakunrin, Akinyemi O. D.;Oguche, Stephen;Sagay, Atiene S.
通讯作者：
Sagay, Atiene S.
影响因子：
168.9
作者：
Wang, Winfred C.;Ware, Russell E.;Thompson, Bruce W.
通讯作者：
Thompson, Bruce W.